# NIH Reporter #5R44HL160338-03

Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.

**Recipient:** Young Therapeutics, LLC

**Award Amount:** $1,488,899.00
**Ceiling:** $1,488,899.00

**Awarded:** June 30, 2026

**Identifier:** 5R44HL160338-03

Funding supports development of targeted PKC inhibitors intended to reduce heart damage and preserve cardiac function after myocardial infarction.

### Description

Phase II SBIR project to develop and validate YT-002 and YT-004, compounds targeting PKCε and PKCβII, to preserve myocardial tissue and function after infarction. The work includes formulation optimization, pharmacokinetic and pharmacodynamic studies, and long-term safety and efficacy studies in porcine models to support potential IND applications.

[View original record](https://reporter.nih.gov/search/0ftClcwKYUOEq8QKPKx2lA/project-details/11310186)